ARS Pharmaceuticals, Inc.
SPRY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $51 | $71 | $211 | $60 |
| Short-Term Investments | $263 | $157 | $64 | $0 |
| Receivables | $9 | $1 | $0 | $0 |
| Inventory | $5 | $0 | $0 | $0 |
| Other Curr. Assets | $6 | $2 | $3 | $1 |
| Total Curr. Assets | $334 | $232 | $278 | $61 |
| Property Plant & Equip (Net) | $1 | $1 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $8 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $8 | $1 | $3 | $0 |
| Total NC Assets | $17 | $2 | $4 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $351 | $233 | $281 | $61 |
| Liabilities | – | – | – | – |
| Payables | $10 | $1 | $2 | $2 |
| Short-Term Debt | $0 | $0 | $0 | $4 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $1 | $0 | $0 | $1 |
| Other Curr. Liab. | $13 | $1 | $4 | $1 |
| Total Curr. Liab. | $23 | $2 | $5 | $8 |
| LT Debt | $0 | $0 | $0 | $5 |
| Deferred Rev, NC | $2 | $0 | $0 | $3 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $69 | $0 | $3 | $76 |
| Total NC Liab. | $71 | $0 | $3 | $85 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $1 |
| Total Liabilities | $94 | $2 | $9 | $93 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$123 | -$131 | -$77 | -$42 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $380 | $362 | $349 | $11 |
| Total Equity | $257 | $231 | $273 | -$31 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $351 | $233 | $281 | $61 |
| Net Debt | -$51 | -$71 | -$210 | -$51 |